CVKD
Cadrenal Therapeutics, Inc. Common Stock·Healthcare
4.76
4.225%(−0.21)
Market ClosedLast Updated: — ET
52W L: $4.2152W H: $17.50
CVKD NEWS
globenewswire.com
Mar 31
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity
globenewswire.com
Mar 12
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes.
globenewswire.com
Mar 2
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors.
defenseworld.net
Mar 2
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 56,472 shares, a decrease of 20.8% from the January 29th total of 71,276 shares. Currently, 3.3% of the shares of the stock are
globenewswire.com
Feb 24
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase 2 trial evaluating CAD-1005 (formerly VLX-1005) in patients with heparin-induced thrombocytopenia (HIT), a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant.
defenseworld.net
Feb 17
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 71,276 shares, a growth of 22.1% from the January 15th total of 58,362 shares. Currently, 4.1% of the shares of the company are
